These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11450879)

  • 1. Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.
    Adorini L
    J Chemother; 2001 Jun; 13(3):219-34. PubMed ID: 11450879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic approaches in multiple sclerosis.
    Adorini L
    J Neurol Sci; 2004 Aug; 223(1):13-24. PubMed ID: 15261555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-based immunointervention in human autoimmune diseases.
    Adorini L
    Trends Biotechnol; 2004 Nov; 22(11):547-9. PubMed ID: 15491794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.
    Kohm AP; Turley DM; Miller SD
    Int Rev Immunol; 2005; 24(5-6):361-92. PubMed ID: 16318987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network.
    Weathington NM; Blalock JE
    Expert Rev Vaccines; 2003 Feb; 2(1):61-73. PubMed ID: 12901598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of T cell responses by protein and peptide-based immunotherapy.
    Adorini L
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S41-4. PubMed ID: 8324949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective immunosuppression of class II-restricted T cells by MHC class II-binding peptides.
    Guéry JC; Adorini L
    Crit Rev Immunol; 1993; 13(3-4):195-206. PubMed ID: 8110375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The trimolecular complex as a target for specific immunotherapy in experimental autoimmune encephalomyelitis--applications for multiple sclerosis and other human autoimmune disease].
    Miller A; Weiner HL; Abramsky O
    Harefuah; 1992 Aug; 123(3-4):110-5. PubMed ID: 1516860
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of protective therapy for autoimmune diseases by targeted DNA vaccines encoding pro-inflammatory cytokines and chemokines.
    Karin N
    Curr Opin Mol Ther; 2004 Feb; 6(1):27-33. PubMed ID: 15011778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects.
    Dalakas MC
    Ann Neurol; 1995 May; 37 Suppl 1():S2-13. PubMed ID: 8968213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective immunosuppression.
    Adorini L; Guéry JC; Rodriguez-Tarduchy G; Trembleau S
    Immunol Today; 1993 Jun; 14(6):285-9. PubMed ID: 8104410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H; Hohlfeld R
    BioDrugs; 2002; 16(3):183-200. PubMed ID: 12102646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines to prevent and treat autoimmune diseases.
    Mor F; Cohen IR
    Int Arch Allergy Immunol; 1995 Dec; 108(4):345-9. PubMed ID: 7580306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multiple sclerosis and experimental autoimmune encephalomyelitis].
    Béraud-Juven E
    Rev Prat; 1994 Jan; 44(1):69-74. PubMed ID: 8178062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell receptor-based immunointervention in autoimmune diseases. Therapeutic use of monoclonal antibodies.
    Chatenoud L; Bach JF
    Immunol Ser; 1993; 59():101-16. PubMed ID: 7681694
    [No Abstract]   [Full Text] [Related]  

  • 16. Antigen-specific therapies in multiple sclerosis.
    Sospedra M; Martin R
    Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis.
    Zhang J
    Expert Rev Vaccines; 2002 Oct; 1(3):285-92. PubMed ID: 12901569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral tolerance in the control of experimental models of autoimmune disease.
    Staines NA; Harper N
    Z Rheumatol; 1995; 54(3):145-54. PubMed ID: 7660685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective immunosuppression.
    Adorini L; Guéry JC; Rodriguez-Tarduchy G; Trembleau S
    Trends Pharmacol Sci; 1993 May; 14(5):178-82. PubMed ID: 8212314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
    Hermans G; Denzer U; Lohse A; Raus J; Stinissen P
    J Autoimmun; 1999 Sep; 13(2):233-46. PubMed ID: 10479392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.